摘要
随着寿命的增长和全科医疗保健的改善,痴呆症呈全球性激增,而阿尔茨海默病(AD)是其最常见的主要原因。从最新的病理学研究的数据显示,实际上其他神经退行性变和血管病变的共同存在已是规律而不是例外。晚发型AD患者在或多或少的程度上几乎总是共同存在脑小血管病(SVD),众所周知,能促进认知功能减退。以往的观察性研究和临床试验在很大程度上试图以主要的神经退行性变或血管机制为基础来划分痴呆。鉴于到其高度的重叠性,从以上的研究结果来看可能难以解释和适用到人群。此外,可能会失去发现新的针对共存的血管和神经退行性病变的相互作用的干预措施的机会。在本综述里,我们认为脑小血管病(SVD)可能与AD有关并促进其病理改变的可能的病理生理机制。我们特别地探索了共享的环境和遗传因素的结合,经神经炎症通路如何将这些因素相联系,可能提供新的治疗靶点。SVD在脑成像和病理上有多元性的临床表现。我们讨论研究SVD的局部解剖学如何使我们能更好地识别那些认知能力讯速下降的风险和提高未来的临床试验设计。
关键词: 阿尔茨海默病,β淀粉样蛋白,载脂蛋白E、脑淀粉样血管病、小血管病、血管危险因素、脑白质高信号
Current Alzheimer Research
Title:Could Better Phenotyping Small Vessel Disease Provide New Insights into Alzheimer Disease and Improve Clinical Trial Outcomes?
Volume: 13 Issue: 7
Author(s): Michael Marnane, Ging-Yuek R. Hsiung
Affiliation:
关键词: 阿尔茨海默病,β淀粉样蛋白,载脂蛋白E、脑淀粉样血管病、小血管病、血管危险因素、脑白质高信号
摘要: Alzheimer Disease (AD) is the most common primary cause of dementia with a burgeoning epidemic as life expectancy and general medical care improve worldwide. Recent data from pathologic studies has shown that the cooccurrence of other neurodegenerative and vascular pathologies is in fact the rule rather than the exception. In late onset AD, cerebral small vessel disease (SVD) is almost invariably co-existent to a greater or lesser extent and is known to promote cognitive deterioration. Previous observational studies and clinical trials have largely sought to divide dementia based on predominant neurodegenerative or vascular mechanisms. Given the high degree of overlap, findings from such studies may be difficult to interpret and apply to population cohorts. Additionally opportunities may be lost for uncovering novel interventions that target interactions between co-existent vascular and neurodegenerative pathologies. In the current review, we consider potential pathophysiologic mechanisms through which SVD may be associated with and promote AD pathology. In particular we explore shared environmental and genetic associations and how these may converge via neuroinflammatory pathways potentially providing novel therapeutic targets. SVD has heterogenous manifestations on cerebral imaging and at pathology. We discuss how studying SVD topography may enable us to better identify those at risk for more rapid cognitive decline and improve future clinical trial design.
Export Options
About this article
Cite this article as:
Michael Marnane, Ging-Yuek R. Hsiung , Could Better Phenotyping Small Vessel Disease Provide New Insights into Alzheimer Disease and Improve Clinical Trial Outcomes?, Current Alzheimer Research 2016; 13 (7) . https://dx.doi.org/10.2174/1567205013666160222112634
DOI https://dx.doi.org/10.2174/1567205013666160222112634 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Pharmacology and Therapeutics of Gabapentin in the Treatment of Psychiatric Disorders; Present and Future Perspectives
Current Neuropharmacology Pleasure as an Overlooked Target of Substance Use Disorder Research and Treatment
Current Drug Abuse Reviews Are Raw Scores on Memory Tests Better than Age- and Education- Adjusted Scores for Predicting Progression from Amnesic Mild Cognitive Impairment to Alzheimer Disease ?
Current Alzheimer Research Recent Approaches Targeting Beta-Amyloid for Therapeutic Intervention of Alzheimer's disease
Recent Patents on CNS Drug Discovery (Discontinued) Beta-Amyloid, Oxidative Stress and Down Syndrome
Current Alzheimer Research Synthetic Curcumin Analogs as Inhibitors of β -Amyloid Peptide Aggregation: Potential Therapeutic and Diagnostic Agents for Alzheimer's Disease
Mini-Reviews in Medicinal Chemistry Sundowning Syndrome: A Possible Marker of Frailty in Alzheimer’s Disease?
CNS & Neurological Disorders - Drug Targets Modulation of the TRPV1 Channel: Current Clinical Trials and Recent Patents with Focus on Neurological Conditions
Recent Patents on CNS Drug Discovery (Discontinued) Tuberculosis Infections of the Central Nervous System
Central Nervous System Agents in Medicinal Chemistry Ginseng for Alzheimer's Disease: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
Current Topics in Medicinal Chemistry Economic Aspects on Drug Therapy of Dementia
Current Pharmaceutical Design Cyclooxygenase Inhibitors: Instrumental Drugs to Understand Cardiovascular Homeostasis and Arterial Thrombosis
Cardiovascular & Hematological Disorders-Drug Targets Getting to Know the Cast - Cellular Interactions and Signaling at the Neurovascular Unit
Current Pharmaceutical Design The Role of Pericytes in Blood-Brain Barrier Function and Stroke
Current Pharmaceutical Design Moderate Wine Consumption in the Prevention of Metabolic Syndrome and its Related Medical Complications
Endocrine, Metabolic & Immune Disorders - Drug Targets Acute Transient Psychoses and their Differentiation from Schizophrenia
Current Psychiatry Reviews The Role of Endothelin-1 in Obstructive Sleep Apnea Syndrome and Pulmonary Arterial Hypertension: Pathogenesis and Endothelin-1 Antagonists
Current Medicinal Chemistry Brain Aging in African-Americans: The Atherosclerosis Risk in Communities (ARIC) Experience
Current Alzheimer Research NAD Metabolism and Functions: A Common Therapeutic Target for Neoplastic, Metabolic and Neurodegenerative Diseases
Current Topics in Medicinal Chemistry Hydrolytic Activity of Amyloid-beta and its Inhibition with Short Peptides
Current Medicinal Chemistry - Central Nervous System Agents